Evaluation of different ways of presenting LipL32 to the immune system with the aim of developing a recombinant vaccine against leptospirosis

Canadian Journal of Microbiology

Volumn 53, Issue 4, 2007, Pages 472-479

  Seixas, Fabiana Kömmling ^a   Fernandes, Claudia Hartleben ^a   Hartwig, Daiane Drawanz ^a   Conceição, Fabricio Rochedo ^a   Aleixo, José Antônio Guimarães ^a   Dellagostin, Odir Antônio ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

DNA vaccine; Leptospira; LipL32; Recombinant BCG; Subunit vaccine

Indexed keywords

DNA VACCINE; LEPTOSPIRA; RECOMBINANT BCG; SUBUNIT VACCINE;

BACTERIA; DNA; HEALTH CARE; IMMUNOLOGY; VACCINES;

DISEASE CONTROL;

BCG VACCINE; DNA VACCINE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LIPL32; PROTEIN LIPL32; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANTIBODY; ANTIGEN; BACTERIAL DISEASE; DNA; IMMUNE RESPONSE; IMMUNE SYSTEM; PROTEIN; RECOMBINATION; SERUM; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG INHIBITION; ESCHERICHIA COLI; FEMALE; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOFLUORESCENCE; IMMUNOGENICITY; LEPTOSPIRA; LEPTOSPIROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; FEMALE; LEPTOSPIRA; LEPTOSPIROSIS; LIPOPROTEINS; MICE; MICE, INBRED BALB C; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

ANIMALIA; ESCHERICHIA COLI; LEPTOSPIRA; MUS;

EID: 34447108853     PISSN: 00084166     EISSN: None     Source Type: Journal    
DOI: 10.1139/W06-138     Document Type: Article

References (29)

1. Bastos, R.G., Dellagostin, O.A., Barletta, R.G., Doster, A.R., Nelson, E., and Osorio, F.A. 2002. Construction and immunogenicity of recombinant Mycobacterium bovis BCG expressing GP5 and M protein of porcine reproductive respiratory syndrome virus. Vaccine, 21: 21-29. doi:10.1016/S0264-410X(02)00443-7.
2. Bradford, M.M. 1976. A rapid and sensitive for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254. doi:10.1016/0003-2697(76)90527-3.
3. Branger, C., Sonrier, C., Chatrenet, B., Klonjkowski, B., Ruvoen-Clouet, N., Aubert, A., Andre-Fontaine, G., and Eloit, M. 2001. Identification of the hemolysis-associated protein 1 as a cross-protective immunogen of Leptospira interrogans by adenovirus mediated vaccination. Infect. Immun. 69: 6831-6838. doi:10.1128/IAI.69.11.6831-6838.2001.
4. Branger, C., Chatrenet, B., Gauvrit, A., Aviat, F., Aubert, A., Bach, J.M., and Andre-Fontaine, G. 2005. Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1. Infect. Immun. 73: 4062-4069. doi:10.1128/IAI.73.7.4062-4069.2005.
5. Cullen, P.A., Xu, X., Matsunaga, J., Sanchez, Y., Ko, A.I., Haake, D.A., and Adler, B. 2005. Surfaceome of Leptospira spp. Infect. Immun. 73: 4853-4863. doi:10.1128/IAI.73.8.4853-4863.2005.
6. Dennehy, M., and Williamson, A.L. 2005. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine, 23: 1209-1224. doi:10.1016/j.vaccine.2004.08.039.
7. Faine, S. 1982. Guidelines for the control of leptospirosis. World Health Organization, Geneva, Switzerland.
8. Flannery, B., Costa, D., Carvalho, F.P., Guerreiro, H., Matsunaga, J., Da Silva, E.D., et al. 2001. Evaluation of recombinant Leptospira antigen-based enzyme-linked immunosorbent assays for the serodiagnosis of leptospirosis. J. Clin. Microbiol. 39: 3303-3310. doi:10.1128/JCM.39.9. 3303-3310.2001.
9. Gitton, X., Daubie, M.B., Andre, F., Ganiere, J.P., and Andre-Fontaine, G. 1994. Recognition of Leptospira interrogans antigens by vaccinated or infected dogs. Vet. Microbiol. 41: 87-97. doi:10.1016/0378-1135(94)90138- 4.
10. Haake, D.A., Chao, G., Zuerner, R.L., Barnett, J.K., Barnett, D., Mazel, M., et al. 2000. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect. Immun. 68: 2276-2285. doi:10.1128/IAI.68.4.2276-2285.2000.
11. Ko, A.I., Galvao, R.M., Ribeiro Dourado, C.M., Johnson, W.D., Jr., and Riley, L.W. 1999. Urban epidemic of severe leptospirosis in Brazil. Salvador Leptospirosis Study Group. Lancet, 354: 820-825.
12. Levett, P.N. 2001. Leptospirosis. Clin. Microbiol. Rev. 14: 296-326. doi:10.1128/CMR.14.2.296-326.2001.
13. Lüdtke, C.B., Coutinho, M.L., Jouglard, S.D.D., Moreira, C.N., Fernandes, C.H.P., Brod, C.S., et al. 2003. Monoclonal antibodies against an outer membrane protein from pathogenic Leptospira. Braz. J. Microbiol. 34: 1-4.
14. Martinez, R., Perez, A., Quinones, M.C., Cruz, R., Alvarez, A., Armesto, M., et al. 2004. Efficacy and safety of a vaccine against human leptospirosis in Cuba. Rev. Panam. Salud Publica, 15: 249-255.
15. McBride, A.J., Athanazio, D.A., Reis, M.G., and Ko, A.I. 2005. Leptospirosis. Curr. Opin. Infect. Dis. 18: 376-386.
16. Medeiros, M.A., Dellagostin, O.A., Armoa, G.R., Degrave, W.M., Mendonca-Lima, L., Lopes, M.Q., et al. 2002. Comparative evaluation of Mycobacterium vaccae as a surrogate cloning host for use in the study of mycobacterial genetics. Microbiology (Reading, U.K.), 148: 1999-2009.
17. Michelon, A., Conceicao, F.R., Binsfeld, P.C., da Cunha, C.W., Moreira, A.N., Argondizzo, A.P., et al. 2006. Immunogenicity of Mycobacterium bovis BCG expressing Anaplasma marginale MSP1a antigen. Vaccine, 24: 6332-6339. doi:10.1016/j.vaccine.2006.05.028.
18. Murray, A., Winter, N., Lagranderie, M., Hill, D.F., Rauzier, J., Timm, J., et al. 1992. Expression of Escherichia coli β-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Mol. Microbiol. 6: 3331-3342. doi:10.1111/j.1365-2958.1992. tb02201.x.
19. Naiman, B.M., Alt, D., Bolin, C.A., Zuerner, R., and Baldwin, C.L. 2001. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and γδ T lymphocytes. Infect. Immun. 69: 7550-7558. doi:10.1128/IAI.69.12.7550-7558.2001.
20. Ohara, N., and Yamada, T. 2001. Recombinant BCG vaccines. Vaccine, 19: 4089-4098. doi:10.1016/S0264-410X(01)00155-4.
21. Ramos, C.R., Abreu, P.A., Nascimento, A.L., and Ho, P.L. 2004. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz. J. Med. Biol. Res. 37: 1103-1109.
22. Sambrook, J., and Russel, D.W. 2001. Molecular cloning. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
23. Shams, H. 2005. Recent developments in veterinary vaccinology. Vet. J. 170: 289-299. doi:10.1016/j.tyjl.2004.07.004.
24. Stover, C.K., de la Cruz, V.F., Fuerst, T.R., Burlein, J.E., Benson, L.A., Bennett, L.T., et al. 1991. New use of BCG for recombinant vaccines. Nature, 351: 456-460. doi:10.1038/351456a0.
25. Stover, C.K., Bansal, G.P., Hanson, M.S., Burlein, J.E., Palaszynski, S.R., Young, J.F., et al. 1993. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178: 197-209. doi:10.1084/jem.178.1.197.
26. Tabata, R., Neto, H.S., Zuanaze, M.A.F., Oliveira, E.M., Dias, R.A., Morais, Z.M., ItoFumio, H., and Vasconcellos, S.A. 2002. Cross neutralizing antibodies in hamsters vaccinated with leptospiral bacterins produced with three serovars of serogroup sejroe. Braz. J. Microbiol. 33: 265-268.
27. Vernel-Pauillac, F., and Merien, F. 2006. Proinflammatory and immunomodulatory cytokine mRNA time course profiles in hamsters infected with a virulent variant of Leptospira interrogans. Infect. Immun. 74: 4172-4179. doi:10.1128/IAI.00447-06.
28. Wolff, J.A., Ludtke, J.J., Acsadi, G., Williams, P., and Jani, A. 1992. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1: 363-369.
29. Yan, Y., Chen, Y., Liou, W., Ding, J., Chen, J., Zhang, J., et al. 2003. An evaluation of the serological and epidemiological effects of the outer envelope vaccine to Leptospira. J. Chin. Med. Assoc. 66: 224-230.